Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Discontinuation Study of BAY 43-9006 in Patients with Advanced Refractory Cancer Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Discontinuation Study of BAY 43-9006 in Patients with Advanced Refractory Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Discontinuation Study of BAY 43-9006 in Patients with Advanced Refractory Cancer Clinical research trials and Discontinuation Study of BAY 43-9006 in Patients with Advanced Refractory Cancer healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Discontinuation Study of BAY 43-9006 in Patients with Advanced Refractory Cancer. Discontinuation Study of BAY 43-9006 in Patients with Advanced Refractory Cancer Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Discontinuation Study of BAY 43-9006 in Patients with Advanced Refractory Cancer clinical trial. Subjects frequently obtain the most expert healthcare possible for their Discontinuation Study of BAY 43-9006 in Patients with Advanced Refractory Cancer condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.

Home > "D" Clinical Trials Conditions > Discontinuation Study of BAY 43-9006 in Patients with Advanced Refractory Cancer

Discontinuation Study of BAY 43-9006 in Patients with Advanced Refractory Cancer



Discontinuation Study of BAY 43-9006 in Patients with Advanced Refractory Cancer

For Condition: Colorectal Neoplasm,Carcinoma, Renal Cell
Status: Recruiting
Sponsor(s): Bayer Corporation , ONYX Pharmaceuticals
Synopsis: The objective of the study is to determine the number/percent of patients with colorectal carcinoma who respond or show stabilization of their disease.
Details:
Eligibility:
Study Type:  Interventional, Treatment, Randomized, Single Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/75 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Age 18 year and older. - Patients with refractory solid cancer for which curative or palliative measures have failed or patients whose treatments are considered ineffective or intolerable. - Patients with non-colorectal cancers are eligible and must be progressing at the time of the screening assessment and for whom no other treatment exists. - Histological or cytological documentation of cancer - ECOG performance status of 0 or 1. - Life-expectancy of at least 12 weeks - Adequate bone marrow, liver function, and renal function. Exclusion Criteria: Patients who meet the following criteria at the time of screening will be excluded: Excluded medical conditions: - NSCLC, Hepatocellular carcinoma, CML, AML - Serious cardiac arrhythmia - Congestive Heart Failure - Active coronary artery disease or ischemia - Active acute infections that could be worsened by anticancer therapy or interfere with this study. - Known HIV infection
Total Enrollment: 

Location and Contact Information:

University of Chicago Medical Center *Recruiting*
Chicago,  Illinois,  60064
United States
Recruiting Mark  Ratain


Additional Information:
Study ID Numbers:  100391; 
Study Start Date: May 2002
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00079612

Other Colorectal Neoplasm Studies:
1. Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

2. Discontinuation Study of BAY 43-9006 in Patients with Advanced Refractory Cancer

3. Advanced Renal Cell Carcinoma

4. Safety/Efficacy of a Vaccine Prepared from Dendritic Cells combined with Tumor Cells to Treat Advanced Kidney Cancer

5. Safety and Efficacy of ABT-510 in Subjects with Advanced Renal Cell Carcinoma

Related Studies:

Other Colorectal Neoplasm Clinical Trials
Other Illinois Clinical Trials
Other Chicago Clinical Trials

Discontinuation Study of BAY 43-9006 in Patients with Advanced Refractory Cancer
Modify your Search

  Other Colorectal Neoplasm Clinical Trials
  Other Illinois Clinical Trials
  Other Chicago Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103